Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Pfizer's Selling, Not Buying, Pipeline Drugs?

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Patent cliffs be damned, Pfizer (NYSE: PFE  ) is selling rather than buying drugs for its pipeline. Yesterday, AstraZeneca (NYSE: AZN  ) announced that it had licensed an oncology compound, tremelimumab, from Pfizer for an undisclosed amount of money.

Why is the pharma giant out-licensing drugs while it's facing the loss of Lipitor to generics next month? Tremelimumab has a checkered past, and it seems that Pfizer has decided to give up on it. Mostly.

Tremelimumab works in much the same way as Bristol-Myers Squibb's (NYSE: BMY  ) Yervoy by activating the patient's immune system to fight melanoma. Unfortunately in 2008, Pfizer stopped a phase 3 trial testing tremelimumab in melanoma patients because the drug wasn't offering any benefit over standard chemotherapy.

Further analysis revealed a biomarker that might predict whether patients would respond to the therapy, and Pfizer licensed the drug to Debiopharm, which was responsible for running a phase 3 trial enrolling patients that would respond. That strategy worked well for Roche's Herceptin and GlaxoSmithKline's (NYSE: GSK  ) Tykerb and might have resulted in an easier approval for Eli Lilly (NYSE: LLY  ) and Bristol-Myers Squibb's (NYSE: BMY  ) Erbitux and Amgen's (Nasdaq: AMGN  ) Vectibix had they discovered the genetic connection earlier.

Fast-forward nearly two years, and it appears Pfizer has regained the rights to tremelimumab; Debiopharm doesn't list the drug on its pipeline page. What's happened during that time isn't clear, but it is clear Pfizer has decided that tremelimumab would be better off in the hands of another company. AstraZeneca bought MedImmune a few years ago so it has plenty of experience with biologics; perhaps it can jump-start the program.

Pfizer isn't completely giving up on tremelimumab though. It's retained the rights to use the drug in combination with other drugs. Bristol and Roche are taking the same tactic with Yervoy and Roche's recently-approved Zelboraf. The theory is that one drug can do the heavy lifting killing the tumor and then the immune system can mop up the remaining cells.

Given Pfizer's revenue predicament, retaining the full rights to tremelimumab would be ideal if the drug works. But given the drug's history, perhaps it's best to just let this one go and focus resources on other potential replacements for Lipitor sales.

Fool contributor Brian Orelli holds no position in any company mentioned. Check out his holdings and a short bio. Motley Fool newsletter services have recommended buying shares of GlaxoSmithKline and Pfizer. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1565070, ~/Articles/ArticleHandler.aspx, 9/29/2016 7:49:10 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,143.45 -195.79 -1.07%
S&P 500 2,151.13 -20.24 -0.93%
NASD 5,269.15 -49.39 -0.93%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/29/2016 4:00 PM
AMGN $165.45 Down -4.26 -2.51%
Amgen CAPS Rating: ****
AZN $33.05 Down -0.77 -2.28%
AstraZeneca CAPS Rating: ****
BMY $53.87 Down -1.22 -2.21%
Bristol-Myers Squi… CAPS Rating: ****
GSK $42.90 Down -0.77 -1.76%
GlaxoSmithKline CAPS Rating: ***
LLY $79.74 Down -0.97 -1.20%
Eli Lilly and Co. CAPS Rating: ***
PFE $33.32 Down -0.67 -1.97%
Pfizer CAPS Rating: ****